| Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging LS Steelman, WH Chappell, SL Abrams, CR Kempf, J Long, P Laidler, ... Aging (Albany NY) 3 (3), 192, 2011 | 793 | 2011 |
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health WH Chappell, LS Steelman, JM Long, RC Kempf, SL Abrams, RA Franklin, ... Oncotarget 2 (3), 135, 2011 | 676 | 2011 |
| GSK-3 as potential target for therapeutic intervention in cancer JA McCubrey, LS Steelman, FE Bertrand, NM Davis, M Sokolosky, ... Oncotarget 5 (10), 2881, 2014 | 538 | 2014 |
| Epidemiology, risk factors, and natural history of hepatocellular carcinoma G Montalto, M Cervello, L Giannitrapani, F Dantona, A Terranova, ... Annals of the New York Academy of Sciences 963 (1), 13-20, 2002 | 493 | 2002 |
| Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB … M Notarbartolo, P Poma, D Perri, L Dusonchet, M Cervello, ... Cancer letters 224 (1), 53-65, 2005 | 427 | 2005 |
| Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response JA McCubrey, LS Steelman, WH Chappell, SL Abrams, G Montalto, ... Oncotarget 3 (9), 954, 2012 | 377 | 2012 |
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance JA McCubrey, LS Steelman, WH Chappell, SL Abrams, RA Franklin, ... Oncotarget 3 (10), 1068, 2012 | 362 | 2012 |
| Sex hormones and risk of liver tumor L Giannitrapani, M Soresi, E La Spada, M Cervello, N D'alessandro, ... Annals of the New York Academy of Sciences 1089 (1), 228-236, 2006 | 355 | 2006 |
| Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention NM Davis, M Sokolosky, K Stadelman, SL Abrams, M Libra, S Candido, ... Oncotarget 5 (13), 4603, 2014 | 315 | 2014 |
| Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention JA McCubrey, LS Steelman, FE Bertrand, NM Davis, SL Abrams, ... Leukemia 28 (1), 15-33, 2014 | 270 | 2014 |
| Targeting the leukemic stem cell: the Holy Grail of leukemia therapy N Misaghian, G Ligresti, LS Steelman, FE Bertrand, J Bäsecke, M Libra, ... Leukemia 23 (1), 25-42, 2009 | 246 | 2009 |
| The tumor microenvironment in hepatocellular carcinoma GC Leonardi, S Candido, M Cervello, D Nicolosi, F Raiti, S Travali, ... International journal of oncology 40 (6), 1733-1747, 2012 | 237 | 2012 |
| Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways JA McCubrey, LS Steelman, CR Kempf, WH Chappell, SL Abrams, ... Journal of cellular physiology 226 (11), 2762-2781, 2011 | 215 | 2011 |
| Targeted therapy for hepatocellular carcinoma: novel agents on the horizon M Cervello, JA McCubrey, A Cusimano, N Lampiasi, A Azzolina, ... Oncotarget 3 (3), 236, 2012 | 211 | 2012 |
| Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs JA McCubrey, K Lertpiriyapong, LS Steelman, SL Abrams, LV Yang, ... Aging (Albany NY) 9 (6), 1477, 2017 | 210 | 2017 |
| Targeting GSK3 and associated signaling pathways involved in cancer P Duda, SM Akula, SL Abrams, LS Steelman, AM Martelli, L Cocco, ... Cells 9 (5), 1110, 2020 | 180 | 2020 |
| Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity—Diverse effects on cell growth, metabolism and cancer JA McCubrey, D Rakus, A Gizak, LS Steelman, SL Abrams, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1863 (12), 2942-2976, 2016 | 172 | 2016 |
| Molecular mechanisms of sorafenib action in liver cancer cells M Cervello, D Bachvarov, N Lampiasi, A Cusimano, A Azzolina, ... Cell cycle 11 (15), 2843-2855, 2012 | 167 | 2012 |
| Akt as a therapeutic target in cancer LS Steelman, KM Stadelman, WH Chappell, S Horn, J Bäsecke, ... Expert opinion on therapeutic targets 12 (9), 1139-1165, 2008 | 164 | 2008 |
| Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells TL Fitzgerald, K Lertpiriyapong, L Cocco, AM Martelli, M Libra, S Candido, ... Advances in biological regulation 59, 65-81, 2015 | 163 | 2015 |
Giuseppe MontaltoBioMedical Department of Internal Medicine and Medical Specialties, University of Palermo,ItalyVerified email at unipa.it
